The Exelon Patch (Transdermal Rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients
A double blinded randomised placebo controlled trial of the exelon patch (transdermal rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients.
Melbourne Health
60 participants
Feb 7, 2010
Interventional
Conditions
Summary
Acetylcholine levels are decreased in delirium, a condition of a sudden change in mental capacity occurring due to a illness, medication or similar insult. Rivastigmine is a medication for Alzhiemer's Disease, another condition where there is a change in mental capacity and low levels of acetylcholine. It increases levels of acetylcholine in the brain. THis trial aims to determine if a rivastigmine patch given to elderly patients in hospital after their illness has resolved but who still have delirium will have a less severe delirium.
Eligibility
Inclusion Criteria1
- Severe Delirium (Confusion assessment method positive, delirium rating scale 12 or more)
Exclusion Criteria4
- Informed consent unable to be obtained
- Deficits in cardiac conducting system, resting pulse <50, intolerance or allergy to rivastigmine, carbamates or excipients.
- Severe dysphasia, visual or hearing impairment, or non english speaking such that unable to complete scales.
- Expected prognosis or discharge less than 2 weeks.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Transdermal Rivastigmine 4.6mg/hour patch applied topically changed daily for two weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609001020279